Login / Signup

Low expression of MEOX2 is associated with poor survival in patients with breast cancer.

Huxia WangYanan TangMeixia WangJing ZhaoCaixia DingXiaomin YangPihua HanPei-Jun Liu
Published in: Biomarkers in medicine (2023)
Aim: To investigate associations of MEOX2 expression with clinicopathological features and survival of breast cancer patients. Materials & methods: We used a breast cancer tissue microarray for immunohistochemistry. Associations between MEOX2 expression and clinicopathological features were analyzed using the χ-square test. Survival analysis was determined using a Kaplan-Meier curve. Multivariate Cox regression was used to determine associations of MEOX2 expression with overall survival. Results: We found that 74.1% of patients (100/135) had expression of MEOX2 at varying levels. MEOX2 was associated with histological grade and negatively correlated with Ki67 expression. Lower MEOX2 expression was significantly associated with decreased overall survival (p = 0.0011). Conclusion: MEOX2 expression could be a novel diagnostic and prognostic biomarker of breast cancer.
Keyphrases
  • poor prognosis
  • binding protein
  • squamous cell carcinoma
  • young adults
  • radiation therapy
  • chronic kidney disease
  • newly diagnosed
  • free survival
  • neoadjuvant chemotherapy